Literature DB >> 1378879

Antigenic diversity of human parainfluenza virus type 1 isolates and their immunological relationship with Sendai virus revealed by using monoclonal antibodies.

H Komada1, S Kusagawa, C Orvell, M Tsurudome, M Nishio, H Bando, M Kawano, H Matsumura, E Norrby, Y Ito.   

Abstract

Fifty-six monoclonal antibodies (MAbs) directed against human parainfluenza virus type 1 (hPIV-1) were prepared in order to identify the structural proteins of hPIV-1, to examine the immunological relationship between hPIV-1 and Sendai virus (SV), and to determine the antigenic diversity of clinical isolates of hPIV-1. In addition, 41 MAbs characterized previously and directed against SV were used for immunological comparison of SV and hPIV-1 isolates. Of the MAbs against hPIV-1, two reacted with phospho (P) protein, 11 with nucleocapsid protein (NP), 24 with haemagglutinin-neuraminidase (HN) protein and 19 with fusion (F) protein. With the aid of MAbs against hPIV-1 and those against SV showing cross-reactivity with hPIV-1, the structural proteins of hPIV-1 were identified; p83, p56, p34, gp74 and gp60 of hPIV-1 were identified as the P, NP, M, HN and F proteins, respectively. The MAbs against the P protein and NP of hPIV-1 showed limited cross-reactivity with SV, whereas they had high reactivity with clinical isolates of hPIV-1. Interestingly, one MAb against the NP of hPIV-1 lacked reactivity with clinical isolates which were isolated in the 1970s and 1980s. The MAbs against the HN of hPIV-1 also exhibited quite limited reactivity with SV and the clinical isolates; two groups of HN-specific MAbs showed almost no reactivity with the clinical isolates from the 1970s and 1980s, similarly to the NP-specific MAb. However, anti-HN MAbs belonging to the two groups showing specific activities (neuraminidase inhibition and haemolysis inhibition) reacted with almost all clinical isolates. On the other hand, although anti-F protein MAbs had limited reactivity with SV, they showed reactivity with almost all hPIV-1 isolates. The MAbs against the P, NP, M, HN and F proteins of SV also showed limited cross-reactivity with the clinical hPIV-1 isolates, and this reactivity was independent of the time and place of isolation, except for that of the F protein. These results confirm that although hPIV-1 is related to SV, it is antigenically distinct from it.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378879     DOI: 10.1099/0022-1317-73-4-875

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  Early stage of establishment of persistent Sendai virus infection: unstable dynamic phase and then selection of viruses which are tightly cell associated, temperature sensitive, and capable of establishing persistent infection.

Authors:  Morihiro Ito; Taijiro Takeuchi; Machiko Nishio; Mitsuo Kawano; Hiroshi Komada; Masato Tsurudome; Yasuhiko Ito
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

2.  Two distinct human parainfluenza virus type 1 genotypes detected during the 1991 Milwaukee epidemic.

Authors:  K J Henrickson; L L Savatski
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

3.  Antigenic diversity in Eimeria maxima and the influence of host genetics and immunization schedule on cross-protective immunity.

Authors:  Adrian L Smith; Patricia Hesketh; Andrew Archer; Martin W Shirley
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

4.  Sendai virus C protein plays a role in restricting PKR activation by limiting the generation of intracellular double-stranded RNA.

Authors:  Kenji Takeuchi; Takayuki Komatsu; Yoshinori Kitagawa; Kiyonao Sada; Bin Gotoh
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

Review 5.  Parainfluenza viruses.

Authors:  Kelly J Henrickson
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

6.  Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates.

Authors:  Emmalene J Bartlett; Ann-Marie Cruz; Janice Esker; Adam Castaño; Henrick Schomacker; Sonja R Surman; Margaret Hennessey; Jim Boonyaratanakornkit; Raymond J Pickles; Peter L Collins; Brian R Murphy; Alexander C Schmidt
Journal:  J Virol       Date:  2008-07-09       Impact factor: 5.103

7.  A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates.

Authors:  Emmalene J Bartlett; Ann-Marie Cruz; Jim Boonyaratanakornkit; Janice Esker; Adam Castaño; Mario H Skiadopoulos; Peter L Collins; Brian R Murphy; Alexander C Schmidt
Journal:  Vaccine       Date:  2009-10-24       Impact factor: 3.641

8.  The C proteins of human parainfluenza virus type 1 block IFN signaling by binding and retaining Stat1 in perinuclear aggregates at the late endosome.

Authors:  Henrick Schomacker; Rebecca M Hebner; Jim Boonyaratanakornkit; Sonja Surman; Emerito Amaro-Carambot; Peter L Collins; Alexander C Schmidt
Journal:  PLoS One       Date:  2012-02-15       Impact factor: 3.240

9.  Hazara Orthonairovirus Nucleoprotein Antagonizes Type I Interferon Production by Inhibition of RIG-I Ubiquitination.

Authors:  Keisuke Ohta; Naoki Saka; Machiko Nishio
Journal:  Viruses       Date:  2022-09-04       Impact factor: 5.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.